However, most such attempts, including a phase II clinical trial conducted by the Pediatric Oncology Group (COG) to test the efficacy of imatinib in a variety of pediatric sarcomas with high c-KIT or PDGFR levels, have failed with poor response 13-15. This evidence concerns the gene PDGFRB and sarcoma.